ArticleCancer letters2010
Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: Complex formation as a mechanism of inactivation.
Article in Cancer letters, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- Construction of a Bayesian network-based risk prediction model for hepatocellular carcinoma in cirrhotic patients.Frontiers in oncology · 2025Article
- Decreased serpin C1 in extracellular vesicles predicts response to methotrexate treatment in patients with pulmonary sarcoidosis.Respiratory research · 2024Article
- MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential.Nature reviews. Urology · 2019Review
- Pleiotropic role of macrophage migration inhibitory factor in cancer.American journal of cancer research · 2019Article
- Informative gene selection and the direct classification of tumors based on relative simplicity.BMC bioinformatics · 2016Article
- Article
- Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Mounting evidence suggests that the pro-inflammatory cytokine macrophage migration inhibitory factor (MIF) may serve as an important link between chronic inflammation and carcinogenesis as evidenced by the increase in serum MIF found in patients with various cancers. The present study identifies anti-thrombin III (ATIII) as an endogenous MIF binding protein, which reduces MIF biological activity. Serum MIF in bladder cancer patients (TCC stage II, n=50) was increased when compared to normal patients (n=50), while ATIII-MIF complexes were decreased in bladder cancer patient serum. These data suggest that increased circulating levels of bioactive MIF are present in bladder cancer patient serum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.